Evidence map›Paper›PMID 29462209›Full record

ArticlePloS one2018

Modulation of the colon cancer cell phenotype by pro-inflammatory macrophages: A preclinical model of surgery-associated inflammation and tumor recurrence.

María Marcuello, Xavier Mayol, Eloísa Felipe-Fumero, Jaume Costa, Laia López-Hierro, Silvia Salvans, Sandra Alonso, Marta Pascual, Luís Grande, Miguel Pera

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Survival of HT29 Cancer Cells Is Affected by IGF1R InhibitionPathology oncology research : POR · 2022
    Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

María MarcuelloColorectal Cancer Research Group, Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Carrer Dr. Aiguader, Barcelona, Spain.
Xavier MayolColorectal Cancer Research Group, Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Carrer Dr. Aiguader, Barcelona, Spain.
Eloísa Felipe-FumeroColorectal Cancer Research Group, Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Carrer Dr. Aiguader, Barcelona, Spain.
Jaume CostaColorectal Cancer Research Group, Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Carrer Dr. Aiguader, Barcelona, Spain.
Laia López-HierroColorectal Cancer Research Group, Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Carrer Dr. Aiguader, Barcelona, Spain.
Silvia SalvansColorectal Cancer Research Group, Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Carrer Dr. Aiguader, Barcelona, Spain.
Sandra AlonsoColorectal Cancer Research Group, Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Carrer Dr. Aiguader, Barcelona, Spain.
Marta PascualColorectal Cancer Research Group, Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Carrer Dr. Aiguader, Barcelona, Spain.
Luís GrandeColorectal Cancer Research Group, Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Carrer Dr. Aiguader, Barcelona, Spain.
Miguel PeraColorectal Cancer Research Group, Cancer Research Program, IMIM (Hospital del Mar Medical Research Institute), Carrer Dr. Aiguader, Barcelona, Spain.ORCID 0000-0001-7764-6481
Hospital Del Mar · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peritoneal infection after colorectal cancer surgery is associated with a higher rate of tumor relapse. We have recently proposed that soluble inflammatory factors released in response to a postoperative infection enhance tumor progression features in residual tumor cells. In an effort to set up models to study the mechanisms of residual tumor cell activation during surgery-associated inflammation, we have analyzed the phenotypic response of colon cancer cell lines to the paracrine effects of THP-1 and U937 differentiated human macrophages, which release an inflammatory medium characteristic of an innate immune response. The exposure of the colon cancer cell lines HT-29 and SW620 to conditioned media isolated from differentiated THP-1 and U937 macrophages induced a mesenchymal-like phenotypic shift, involving the activation of in vitro invasiveness. The inflammatory media activated the β-catenin/TCF4 transcriptional pathway and induced the expression of several mesenchymal (e.g., FN1 and VIM) and TCF4 target genes (e.g., MMP7, PTGS2, MET, and CCD1). Similarly, differential expression of some transcription factors involved in epithelial-to-mesenchymal transitions (i.e. ZEB1, SNAI1, and SNAI2) was variably observed in the colon cancer cell lines when exposed to the inflammatory media. THP-1 and U937 macrophages, which displayed characteristics of M1 differentiation, overexpressed some cytokines previously shown to be induced in colorectal cancer patients with increased rates of tumor recurrence associated with postoperative peritoneal infections, thus suggesting their pro-tumoral character. Therefore, the environment created by inflammatory M1 macrophages enhances features of epithelial-to-mesenchymal transition, and may be useful as a model to characterize pro-inflammatory cytokines as putative biomarkers of tumor recurrence risk.

Indexed as

Animalsbeta CateninCell DeathCell Line, TumorCell MovementCell ProliferationColonic NeoplasmsCulture Media, ConditionedDisease Models, AnimalEpithelial-Mesenchymal TransitionHumansInflammationMacrophagesNeoplasm InvasivenessNeoplasm Recurrence, LocalPostoperative Complicationsbeta CateninCulture Media, ConditionedTranscription Factor 4

Identifiers

PMID29462209
PMCPMC5819803
OpenAlexW2790308484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.